AstraZeneca at #ASH24 (Max Gelman for Endpoints News)
December 8, 2024 07:37 PM EST
R&D

As­traZeneca re­veals first clin­i­cal da­ta for bis­pe­cif­ic T cell en­gager from TeneoT­wo buy­out

Max Gelman

Senior Editor

SAN DIEGO — As­traZeneca is get­ting ready to step on the gas in the world of bis­pe­cif­ic T cell en­gagers.

The com­pa­ny pre­sent­ed some of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Pfiz­er’s prostate can­cer da­ta leak shows promis­ing re­sults in ear­ly-stage study

No­var­tis re­turns for its an­ti­co­ag­u­lant in up to $3.1B buy of Black­stone’s An­thos

Judge halts some NIH cuts af­ter 22 states sue

Ver­tex op­er­a­tions chief Stu­art Ar­buck­le to re­tire

Mer­ck KGaA con­firms in­ter­est in ac­quir­ing can­cer biotech Spring­Works

sponsored

Re­duc­ing risk in drug de­vel­op­ment: The im­por­tance of val­i­dat­ed MRD test­ing in lym­phoid can­cers

A service from the Financial Times